These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 39201535)

  • 1. Pramipexole Hyperactivates the External Globus Pallidus and Impairs Decision-Making in a Mouse Model of Parkinson's Disease.
    Kubota H; Zhou X; Zhang X; Watanabe H; Nagai T
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease.
    Li C; Guo Y; Xie W; Li X; Janokovic J; Le W
    Neurochem Res; 2010 Oct; 35(10):1546-56. PubMed ID: 20635141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.
    Deutschländer A; la Fougère C; Boetzel K; Albert NL; Gildehaus FJ; Bartenstein P; Xiong G; Cumming P
    Neuroimage Clin; 2016; 12():41-6. PubMed ID: 27408789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
    Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T
    Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice.
    Lieberknecht V; Junqueira SC; Cunha MP; Barbosa TA; de Souza LF; Coelho IS; Santos AR; Rodrigues AL; Dafré AL; Dutra RC
    Mol Neurobiol; 2017 Mar; 54(2):1033-1045. PubMed ID: 26801190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson's disease.
    Wei SZ; Yao XY; Wang CT; Dong AQ; Li D; Zhang YT; Ren C; Zhang JB; Mao CJ; Wang F; Liu CF
    Brain Res Bull; 2021 Dec; 177():363-372. PubMed ID: 34699917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reinforcing properties of Pramipexole in normal and parkinsonian rats.
    Engeln M; Ahmed SH; Vouillac C; Tison F; Bezard E; Fernagut PO
    Neurobiol Dis; 2013 Jan; 49():79-86. PubMed ID: 22940424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole enhances disadvantageous decision-making: Lack of relation to changes in phasic dopamine release.
    Pes R; Godar SC; Fox AT; Burgeno LM; Strathman HJ; Jarmolowicz DP; Devoto P; Levant B; Phillips PE; Fowler SC; Bortolato M
    Neuropharmacology; 2017 Mar; 114():77-87. PubMed ID: 27889491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three paradoxes related to the mode of action of pramipexole: The path from D2/D3 dopamine receptor stimulation to modification of dopamine-modulated functions.
    Szabadi E
    J Psychopharmacol; 2024 Jul; 38(7):581-596. PubMed ID: 39041250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting.
    Floris G; Scheggi S; Pes R; Bortolato M
    Brain Res Bull; 2022 Apr; 181():157-166. PubMed ID: 35122898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
    Seeman P
    Synapse; 2015 Apr; 69(4):183-9. PubMed ID: 25645960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model.
    Winner B; Desplats P; Hagl C; Klucken J; Aigner R; Ploetz S; Laemke J; Karl A; Aigner L; Masliah E; Buerger E; Winkler J
    Exp Neurol; 2009 Oct; 219(2):543-52. PubMed ID: 19619535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct effects of pramipexole on the proliferation of adult mouse sub-ventricular zone-derived cells and the appearance of a neuronal phenotype.
    Merlo S; Canonico PL; Sortino MA
    Neuropharmacology; 2011 May; 60(6):892-900. PubMed ID: 21272591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the globus pallidus D2 subfamily of dopamine receptors in pallidal immediate early gene expression.
    Marshall JF; Henry BL; Billings LM; Hoover BR
    Neuroscience; 2001; 105(2):365-78. PubMed ID: 11672604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease.
    Jiménez-Urbieta H; Gago B; Quiroga-Varela A; Rodríguez-Chinchilla T; Merino-Galán L; Oregi A; Belloso-Iguerategui A; Delgado-Alvarado M; Navalpotro-Gómez I; Marin C; Fernagut PO; Rodríguez-Oroz MC
    Neurobiol Aging; 2019 Mar; 75():126-135. PubMed ID: 30572183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adverse effects of pramipexole on probability discounting are not reversed by acute D
    Orrù M; Strathman HJ; Floris G; Scheggi S; Levant B; Bortolato M
    Eur Neuropsychopharmacol; 2020 Mar; 32():104-119. PubMed ID: 31983530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
    Paul ML; Graybiel AM; David JC; Robertson HA
    J Neurosci; 1992 Oct; 12(10):3729-42. PubMed ID: 1357113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson's disease.
    Dong AQ; Yang YP; Jiang SM; Yao XY; Qi D; Mao CJ; Cheng XY; Wang F; Hu LF; Liu CF
    Acta Pharmacol Sin; 2023 Jan; 44(1):32-43. PubMed ID: 35896696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine agonist increases risk taking but blunts reward-related brain activity.
    Riba J; Krämer UM; Heldmann M; Richter S; Münte TF
    PLoS One; 2008 Jun; 3(6):e2479. PubMed ID: 18575579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.